Öz
Amaç: Bu çalışmanın amacı, ileri glikasyon son ürünlerinin öncülü olan glioksalin (GO), koronavirüs hastalığı-2019 (COVID-19) nedeniyle hastanede tedavi gören benzer yaş ve benzer komorbiditeli hastalık şiddetine sahip diyabeti ve diyabeti olmayan hastalardaki etkisini araştırmaktır.
Yöntemler: Çalışmaya 57 hasta dahil edildi. GO ölçümü yüksek performanslı sıvı kromatografi yöntemiyle yapıldı.
Bulgular: Glioksal değerleri diyabetik grupta diyabetik olmayan gruba göre daha yüksek bulundu (p=0,001, p<0,01). Hastanede kalış süresi diyabetik grupta daha uzundu (p=0,017, p<0,05). Beyaz kan hücresi, nötrofil, nötrofil/lenfosit oranı, prokalsitonin ve ferritin değerlerinin diyabetik grupta diyabetik olmayan gruba göre daha yüksek olduğu belirlendi (p=0,006; p=0,005, p=0,017, p=0,011, p=0,030). Benzer yaştaki, komorbiditeleri ve COVID-19 şiddeti benzer olan diyabetik ve diyabetik olmayan hastalarda mortalite ve yoğun bakıma yatış oranları benzer olmasına rağmen, diyabetik hastaların hastanede toplam kalış süresinin daha uzun olduğu belirlendi. Diğer enflamasyon belirteçleriyle birlikte GO’nun diyabetik grupta daha yüksek olduğu belirlendi.
Sonuç: Bu çalışmanın sonuçları, yüksek GO’nun COVID-19’da uzun süreli iyileşme süresiyle ilişkili olabileceğini gösterdi.
Anahtar Kelimeler: İleri glikasyon son ürünleri, COVID-19, diyabet, glioksal, hastanede kalış süresi
Kaynakça
COVID-19 Coronavirus Pandemic. [homepage on the Internet] [Last updated: August 16, 2023]. Available from:https://www.worldometers.info/coronavirus/
Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146:110-8.
Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep. 2004;53:1066-8.
Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Götting C, et al. Effects of low-and high-advanced glycation endproduct meals on macro-and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2007;85:1236-43.
Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med. 2002;251:87-101.
Aragno M, Mastrocola R. Dietary Sugars and Endogenous Formation of Advanced Glycation Endproducts: Emerging Mechanisms of Disease. Nutrients. 2017;9:385.
Livesey G, Taylor R, Hulshof T, Howlett J. Glycemic response and health--a systematic review and meta-analysis: relations between dietary glycemic properties and health outcomes. Am J Clin Nutr. 2008;87:258-68.
Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets. 2007;8:952-9.
Yamagishi S, Matsui T. Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention. Nutrition. 2016;32:157-65.
American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):14-31.
Cengiz S, Kişmiroğlu C, Cebi N, Çatak J, Yaman M. Determination of the most potent precursors of advanced glycation end products (AGEs) in chips, crackers, and breakfast cereals by high performance liquid chromatography (HPLC) using precolumn derivatization with 4-nitro-1, 2-phenlenediamine. Microchemical J. 2020;158:105170.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-42.
Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2020;14:535-45.
Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N, et al. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality. Cell Metab. 2018;28:337-52.
Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93:250-6.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson Jjet al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-4.
Chinese Clinical Trial Registry, A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19);2020. [homepage on the Internet] [Accessed March 6, 2020]. Available from Availed from:http://www.chictr.org.cn/showprojen.aspx?proj=49409
Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8:1233-44.
Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44:129-46.
Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl). 2005;83:876-86.
Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-21.
